Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug

20-08-2019

Sarah Morgan

Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug

Pavel Kapysh / Shutterstock.com

Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.


Amneal, Sun Pharma, Upsher-Smith Laboratories, Wockhardt, Actavis, Forest, antitrust, Alzheimer’s, generics, Namenda

LSIPR